Collection / ARA-290
ARA-290
ARA-290, also called cibinetide, is an erythropoietin-derived peptide studied in tissue-response and small-fibre neuropathy research. A small pilot trial offers a focused exploratory clinical context.
Simulation only · No real order or payment.
11-amino-acid peptide derived from erythropoietin
Also known as: Cibinetide
Human trialResearch & handling
Not for human or veterinary use. Storage, handling, identity and purity require verified batch documentation. No dosing or treatment advice is provided.
At a glance
Derived peptide
The eleven-amino-acid material is distinct from full erythropoietin.
Small-fibre research
Reviewed pilot evidence concerns sarcoidosis-associated symptoms.
Exploratory endpoints
Short-term symptom scores do not establish broad or long-term treatment efficacy.
Explore the study context and sources below. For laboratory research only.
Studies & context
Studied in a small pilot trial in adults with sarcoidosis-associated small-fibre neuropathy for symptom-score changes.
Human trialThe four-week randomized pilot in 22 patients reported greater improvement in the small-fibre neuropathy screening score with ARA-290 than placebo.
Study limitations
A small exploratory study, not established treatment efficacy.
Pain-inventory and fatigue scores improved similarly in both groups; no safety concerns emerged from the short clinical and laboratory assessments.
Study limitations
These results do not establish long-term safety or broad pain relief.
Published research is separate from PEPTIVIA identity, content, purity, sterility and batch documentation. No source-supplier report verifies PEPTIVIA material.